HLA‐DQ‐conferred risk for type 1 diabetes does not alter neutralizing antibody response to a widely used enterovirus vaccine, the poliovirus vaccine

This study investigated whether children with HLA‐DQ‐conferred risk for type 1 diabetes (T1D) have an altered immune response to the widely‐used enterovirus vaccine, namely poliovirus vaccine, and whether initiation of autoimmunity to pancreatic islets modulates this response. Neutralizing antibodies induced by the inactivated poliovirus vaccine against poliovirus type 1 (Salk) were analysed as a marker of protective immunity at the age of 18 months in a prospective birth cohort. No differences were observed in antibody titers between children with and without genetic risk for T1D (odds ratio [OR] = 0.90 [0.83, 1.06], p = 0.30). In the presence of the genetic risk, no difference was observed between children with and without islet autoimmunity (OR = 1.00 [0.78, 1.28], p = 1.00). This did not change when only children with the autoimmunity before 18 months of age were included in the analyses (OR = 1.00 [0.85, 1.18], p = 1.00). No effect was observed when groups were stratified based on autoantigen specificity of the first‐appearing autoantibody (IAA or GADA). The children in each comparison group were matched for sex, calendar year and month of birth, and municipality. Accordingly, we found no indication that children who are at risk to develop islet autoimmunity would have a compromised humoral immune response which could have increased their susceptibility for enterovirus infections. In addition, the proper immune response supports the idea of testing novel enterovirus vaccines for the prevention of T1D among these individuals.

[1]  W. Hagopian,et al.  Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children. , 2021, Diabetes care.

[2]  N. V. Kuzmenko,et al.  Seasonal Body Weight Dynamics in Healthy People: A Meta-Analysis , 2021, Human Physiology.

[3]  M. Horwitz,et al.  Virus Infection Is an Instigator of Intestinal Dysbiosis Leading to Type 1 Diabetes , 2021, Frontiers in Immunology.

[4]  V. Hytönen,et al.  Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect , 2021, Diabetes.

[5]  Yeping Wang,et al.  Association Between Enterovirus Infection and Type 1 Diabetes Risk: A Meta-Analysis of 38 Case-Control Studies , 2021, Frontiers in Endocrinology.

[6]  O. Laitinen,et al.  A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates , 2020, Science Advances.

[7]  P. Woo,et al.  Correction to: Recommendations for the nomenclature of enteroviruses and rhinoviruses , 2020, Archives of Virology.

[8]  Mark S. Anderson,et al.  Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes , 2019, Diabetes Care.

[9]  V. Tromba,et al.  How diabetes type 1 affects immune response to hepatitis B virus vaccine in pediatric population? Evaluation of a booster dose in unresponsive subjects with type 1 diabetes. , 2019, Minerva pediatrica.

[10]  R. Gibbs,et al.  Prospective virome analyses in young children at increased genetic risk for type 1 diabetes , 2019, Nature Medicine.

[11]  M. Knip,et al.  Developing a vaccine for type 1 diabetes by targeting coxsackievirus B , 2018, Expert review of vaccines.

[12]  N. Morgan,et al.  Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells , 2018, Diabetologia.

[13]  Chia-Ling Kuo,et al.  Unconditional or Conditional Logistic Regression Model for Age-Matched Case–Control Data? , 2018, Front. Public Health.

[14]  J. Ilonen,et al.  Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes , 2018, Diabetologia.

[15]  J. Ilonen,et al.  Detection of enteroviruses in stools precedes islet autoimmunity by several months: possible evidence for slowly operating mechanisms in virus-induced autoimmunity , 2017, Diabetologia.

[16]  E. Bonifacio,et al.  Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin , 2016, Scientific Reports.

[17]  J. Ilonen,et al.  Genetic susceptibility to type 1 diabetes in childhood – estimation of HLA class II associated disease risk and class II effect in various phases of islet autoimmunity , 2016, Pediatric diabetes.

[18]  V. Hackethal.  Childhood Vaccinations and Type 1 Diabetes , 2015 .

[19]  R. Purcell,et al.  A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  E. Bonifacio,et al.  The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study , 2015, Diabetologia.

[21]  E. Valletta,et al.  Normal or defective immune response to Hepatitis B vaccine in patients with diabetes and celiac disease , 2015, Human vaccines & immunotherapeutics.

[22]  M. Knip,et al.  A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models , 2015, Diabetologia.

[23]  Walter Ricciardi,et al.  The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses. , 2014, Vaccine.

[24]  J. Ilonen,et al.  Virus Antibody Survey in Different European Populations Indicates Risk Association Between Coxsackievirus B1 and Type 1 Diabetes , 2014, Diabetes.

[25]  J. Ilonen,et al.  Coxsackievirus B1 Is Associated With Induction of β-Cell Autoimmunity That Portends Type 1 Diabetes , 2014, Diabetes.

[26]  J. Ilonen,et al.  The HLA-B*39 allele increases type 1 diabetes risk conferred by HLA-DRB1*04:04-DQB1*03:02 and HLA-DRB1*08-DQB1*04 class II haplotypes. , 2014, Human Immunology.

[27]  H. Zhuang,et al.  The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. , 2013, Vaccine.

[28]  E. Bonifacio,et al.  Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. , 2013, JAMA.

[29]  J. Ilonen,et al.  Virus Antibody Survey in Different European Populations Indicates Risk Association Between Coxsackievirus B 1 and Type 1 Diabetes Running title : Group B Coxsackievirus Infections and Type 1 Diabetes , 2013 .

[30]  V. Mohan,et al.  Suggested use of vaccines in diabetes , 2012, Indian journal of endocrinology and metabolism.

[31]  G. Marseglia,et al.  Hepatitis B vaccination failure in children with Diabetes Mellitus? The debate continues , 2012, Human vaccines & immunotherapeutics.

[32]  H. Siljander,et al.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial , 2008, The Lancet.

[33]  S. Rapola.  National immunization program in Finland , 2007, International journal of circumpolar health.

[34]  N. Nathanson.  David Bodian's contribution to the development of poliovirus vaccine. , 2005, American journal of epidemiology.

[35]  M. Eibl,et al.  Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. , 2002, Clinical immunology.

[36]  P. Bingley,et al.  Progression to diabetes in relatives with islet autoantibodies. Is it inevitable? , 1999, Diabetes care.

[37]  M. Pallansch.  Coxsackievirus B epidemiology and public health concerns. , 1997, Current topics in microbiology and immunology.

[38]  K. Taylor,et al.  Coxsackie B virus infection and onset of childhood diabetes , 1995, The Lancet.

[39]  A. Notkins,et al.  PANCREATIC ISLET-CELL DAMAGE IN CHILDREN WITH FATAL VIRAL INFECTIONS , 1980, The Lancet.